# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

### FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) March 5, 2013

### Pacific Biosciences of California, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 001-34899 (Commission File Number) 16-1590339 (IRS Employer Identification No.)

1380 Willow Road Menlo Park, California 94025 (Address of principal executive offices, including zip code)

(650) 521-8000

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

ck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following isions (see General Instruction A.2):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS

(b) On March 5, 2013, Susan Siegel, a Class I director, announced her resignation from the Board of Directors of Pacific Biosciences of California, Inc. (the "Company"), which resignation will be effective on or before the Company's 2013 Annual Meeting of Stockholders.

On March 5, 2013, David Singer, a Class III director, informed the Company that he has chosen not to stand for re-election at the Company's 2013 Annual Meeting of Stockholders. Mr. Singer has indicated his intention to continue to serve as a director until the Company's 2013 Annual Meeting of Stockholders.

#### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Pacif	fic Biosciences of California, Inc.
By:	/ S / Brian B. Dow
_	Brian B. Dow Vice President and Principal Accounting Officer

Date: March 7, 2013